Deals· August 6, 2026 · 13 min read
Gilead's $7.8B Arcellx Acquisition: Anito-Cel Deal Anatomy
By Ran Chen#Gilead Sciences#Arcellx#anito-cel
Topic
CAR-T
CAR-T approvals, site readiness, inpatient/outpatient economics, outcomes evidence, and payer access.
Pipeline· August 2, 2026 · 26 min read
In Vivo CAR-T by the Numbers 2026: $17.9B in Deals vs 23 Phase 1 Trials
By Ran Chen#CAR-T#Clinical Trials#Oncology
Pipeline· July 17, 2026 · 17 min read
Cell & Gene Therapy Trials by the Numbers: The 2026 Registry Landscape
By Ran Chen#Gene Therapy#CAR-T#Clinical Evidence
Pricing & Access· July 12, 2026 · 20 min read
Lupus and SLE Access: Benlysta, Saphnelo, Lupkynis, and Autoimmune CAR-T
By Ran Chen#Payer Coverage#Payer Criteria#CAR-T
Evidence· June 13, 2026 · 11 min read
EULAR 2026 readouts: CD40L lupus win, IL-17 beats IL-23, off-the-shelf cell therapy
By Ran Chen#Immunology#Clinical Evidence#Pivotal Trials
Pricing & Access· June 10, 2026 · 10 min read
Bispecific antibody access landscape for myeloma and lymphoma
Pricing & Access· June 10, 2026 · 9 min read
CAR-T cell therapy access landscape: seven products in 2026
By Ran Chen#CAR-T#Oncology#Prior Authorization
Manufacturing· June 9, 2026 · 6 min read
The commercial ecosystem behind cell & gene therapy: ASGCT 2026 exhibitors mapped
Pricing & Access· May 27, 2026 · 12 min read
Yescarta vs Tecartus CAR-T access guide
By Ran Chen#Oncology#CAR-T#Prior Authorization